Vera Therapeutics (VERA)

Company Profile

Vera Therapeutics, Inc., (the Company) is a clinical late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The Company is headquartered in Brisbane, California and was incorporated in May 2016 in Delaware. In 2017, the Company acquired all of the outstanding shares of PNA Innovations, Inc. (PNAi), which was based in Woburn, Massachusetts.

Company profile

Ticker

VERA

Exchange

Incorporated

Location

Fiscal year end

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001831828

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

IRS number

812744449

VERA stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$16.75

Low target

$6.00

High target

$38.00

Latest filings (excl ownership)

View all

Prospectus supplement for primary offering

2 Feb 23

424B5

Prospectus supplement for primary offering

1 Feb 23

8-K

Results of Operations and Financial Condition

1 Feb 23

8-K

Regulation FD Disclosure

30 Jan 23

8-K

Regulation FD Disclosure

9 Nov 22

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

9 Nov 22

8-K

Entry into a Material Definitive Agreement

9 Sep 22

424B5

Prospectus supplement for primary offering

9 Sep 22

Latest ownership filings

View all

SC 13G/A

Kleiner Perkins Caufield & Byers XVI, LLC

Financial summary

Financial statements Chart VERA financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	30.77 mm	30.77 mm	30.77 mm	30.77 mm	30.77 mm	30.77 mm
Cash burn (monthly)	6.65 mm	4.64 mm	8.41 mm	6.16 mm	6.14 mm	4.41 mm
Cash used (since last report)	27.79 mm	19.40 mm	35.17 mm	25.74 mm	25.66 mm	18.41 mm
Cash remaining	2.97 mm	11.36 mm	-4.40 mm	5.03 mm	5.11 mm	12.35 mm
Runway (months of cash)	0.4	2.4	-0.5	0.8	0.8	2.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2022

VERA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	54	52	+3.8%
Opened positions	7	15	-53.3%
Closed positions	5	2	+150.0%
Increased positions	20	24	-16.7%
Reduced positions	11	7	+57.1%

13F shares	Current	Prev Q	Change
Total value	687.51 mm	594.79 mm	+15.6%
Total shares	27.78 mm	27.06 mm	+2.7%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
FMR	4.02 mm	$54.65 mm	+0.1%
Longitude Capital Partners IV	3.43 mm	$61.05 mm	0.0%
Sofinnova Investments	3.18 mm	$43.30 mm	0.0%
Abingworth	2.96 mm	$40.29 mm	0.0%
Sofinnova Venture Partners X	2.91 mm	$36.00 mm	0.0%
Citadel Advisors	2.12 mm	$28.89 mm	+1.6%
Ra Capital Management	1.58 mm	$21.49 mm	-19.7%
Kynam Capital Management	1.52 mm	$20.72 mm	+203.1%
Kleiner Perkins Caufield & Byers XVI	1.34 mm	$35.89 mm	0.0%
BLK Blackrock	717.03 k	$9.76 mm	+5.5%

Largest transactions	Shares	Bought/sold	Change
Kynam Capital Management	1.52 mm	+1.02 mm	+203.1%
Ra Capital Management	1.58 mm	-387.26 k	-19.7%
Logos Global Management	0.00	-385.00 k	EXIT
Polar Asset Management Partners	294.30 k	+234.30 k	+390.5%
International Biotechnology Trust	3.83 k	-186.92 k	-98.0%
Millennium Management	276.24 k	+142.74 k	+106.9%
BMO Bank of Montreal	96.85 k	+96.85 k	NEW
Maven Securities	0.00	-64.24 k	EXIT
Vanguard	676.94 k	+58.93 k	+9.5%
STT State Street	222.26 k	+53.50 k	+31.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

VERA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Dec 22	Joanne Curley	Class A Common Stock	Sell	Dispose S	No	Yes	20.1697	783	15.79 k	26,821
16 Dec 22	Joanne Curley	Class A Common Stock	Option exercise	Acquire M	No	No	2.8968	783	2.27 k	27,604
16 Dec 22	Joanne Curley	Class A Common Stock	Sell	Dispose S	No	Yes	19.1204	1,429	27.32 k	26,821
16 Dec 22	Joanne Curley	Class A Common Stock	Option exercise	Acquire M	No	No	2.8968	1,429	4.14 k	28,250
16 Dec 22	Joanne Curley	Stock Option Class A Common Stock	Option exercise	Dispose M	No	No	2.8968	2,212	6.41 k	35,801
13 Dec 22	Joanne Curley	Class A Common Stock	Sell	Dispose S	No	Yes	18.19	1,078	19.61 k	26,821
13 Dec 22	Joanne Curley	Class A Common Stock	Option exercise	Acquire M	No	No	6.3728	1,078	6.87 k	27,899
13 Dec 22	Joanne Curley	Class A Common Stock	Sell	Dispose S	No	Yes	18.2767	11,733	214.44 k	26,821
13 Dec 22	Joanne Curley	Class A Common Stock	Option exercise	Acquire M	No	No	11	11,733	129.06 k	38,554
13 Dec 22	Joanne Curley	Stock Options Class A Common Stock	Option exercise	Dispose M	No	No	6.3728	1,078	6.87 k	8,639